News

10.11.2020
GenScript Biotech and medac GmbH Enter into Exclusive Agreement to Distribute World's First SARS-CoV-2 Neutralizing Antibody Detection Kit in Germany and Austria
GenScript Biotech and medac GmbH Enter into Exclusive Agreement to Distribute World's First SARS-CoV-2 Neutralizing Antibody Detection Kit in Germany and Austria

The cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit can be performed within an hour in standard laboratories, making it broadly accessible to patients and healthcare systems
   
LEIDEN, the Netherlands / WEDEL, Germany 10.11.2020
GenScript Biotech Corp. and medac GmbH announced today an exclusive agreement to distribute the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in the German and Austrian markets. The cPass™ kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), a subset of antibodies that can block the ability of SARS-CoV-2 (the virus that causes COVID-19) to enter a cell. It is the only neutralizing antibody detection kit that has received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) and will be CE marked by end of December 2020.
   
“The race to develop a vaccine for SARS-CoV-2 is entering a critical stretch, and we foresee increasing demand for neutralization antibody detection in the latter stages of vaccine development. As an industry leader with a proven track record of success in the area of urological, oncological, hematological and autoimmune therapeutics medac offers precise, patient-specific diagnostics, and is therefore an ideal partner to distribute our cPass™ kit quickly and successfully to the German and Austrian market,” said Zhenyu (Patrick) Liu, CEO of GenScript Biotech Corporation.
   
Neutralizing antibodies are widely recognized biomarkers of immunity. The cPass™ test measures the presence of neutralizing antibodies in any sample, from patients recovering from COVID-19 or those vaccinated against SARS-CoV-2. Detecting the presence of neutralizing antibodies using the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit can also be done within about an hour in most standard research or clinical diagnostic laboratories. This in contrast to conventional neutralizing antibody tests that use live virus and must be performed in a high safety level facility (BSL3). Typically, results from the live virus assay are available in several days.
   
“medac is proud to offer the first SARS-CoV-2 Neutralization Antibody Detection kit to patients and healthcare systems in the German and Austrian markets," said Dr. Lasse Lehnert, CCO of medac, Gesellschaft für klinische Spezialpräparate mbH. „We are very delighted partner with GenScript. The cPass™ Test offers critical information to healthcare providers and patients, enabling them to make informed decisions about their healthcare and how to best protect those around them. The Neutralization Antibody Detection Kits perfectly complete our diagnostics portfolio and already existing products for SARS-CoV-2 detection.
   
About GenScript Biotech Corporation
GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on ist leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform, and the industrial synthesis product platform.
   
GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript's business operation spans over 100 countries and regions worldwide, with legal entities located in the U.S., Mainland China, Hong Kong, Japan, Singapore, Netherlands, and Ireland. GenScript has provided premium, convenient, and reliable products, and services for over 100,000 customers.
   
GenScript has many intellectual property rights and technical secrets, including more than 100 patents and over 270 patent applications. As of June 30, 2020, GenScript's products and services have been cited by 51,000 peer-reviewed journal articles worldwide.
   
About medac GmbH
   
About medac
medac is a privately held, global pharmaceutical company with a growing pharmaceutical and diagnostics business. Established in 1970 in Northern Germany, medac is specialized in the treatment of urological, oncological, hematological and autoimmune diseases as well as in the development of diagnostic devices. Besides an already established product portfolio, medac is dedicated to the refinement of existing and the development of new therapeutic products providing patients with leading-edge individualized treatments. In the field of urology medac focuses on instillation therapies for non-muscle invasive bladder cancer.
   
As the only pharmaceutical company in Germany, medac supplies diagnostic and therapeutic agents from ist own development and production. In the area of personalized medicine medac offers precise, patient-specific diagnostics for optimizing therapeutic measures and achieving the best possible treatment outcome.

News archive